BioSpace News Archive

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO for the treatment of solid tumors and tumor metastases, today announced that it initiated screening patients for its at-home pilot trial with LungFit™ GO for the treatment of NTM lung disease.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, presents new positive efficacy data from its ongoing Phase II ALICE trial, which is investigating iadademstat in combination with azacitidine in elderly patients with acute myeloid leukemia (AML)

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced it received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) on December 3, 2020 regarding the Company’s New Drug Application (“NDA”) for FUROSCIX®.

The Collaboration will Accelerate the Research and Development of Next-generation Immuno-Oncology Therapies

Sequana Medical NV announces that it will hold a key opinion leader event on the challenge of diuretic resistance in the management of heart failure patients and the potential for alfapump® DSR therapy, on Friday 11 December 2020 at 03:00 pm CET / 09:00 am EST.

Blood plasma refers to the liquid part of the blood. It is a versatile element and it comprises around 55% of the blood.

AI in diagnostic imaging is gaining prominence and quickly growing industry close to what’s to come.

The luciferase assay is utilized in the determination of whether a protein can repress or activate the expression of a gene that has been targeted.

The high prevalence of infectious diseases globally, rapidly aging population, growing demand for point-of-care testing, and home-based lateral flow assay devices are the major factors driving the growth of this market.

The study confirms the potential of eryaspase as an attractive treatment option for ALL patients with hypersensitivity to PEG-asparaginase